^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Esophageal and Esophagogastric Junction Cancers: First-line Therapy...Oxaliplatin is generally preferred over cisplatin due to lower toxicity.
